Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Upgraded by JonesTrading

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by research analysts at JonesTrading from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a $25.00 price target on the biotechnology company’s stock. JonesTrading‘s price target suggests a potential upside of 127.03% from the company’s previous close.

A number of other equities research analysts have also commented on the stock. Cantor Fitzgerald raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. B. Riley Financial raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $5.00 to $21.00 in a research note on Monday, September 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Ladenburg Thalmann & Co. Inc. cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Finally, HC Wainwright downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, July 27th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics presently has a consensus rating of “Hold” and an average target price of $29.77.

Capricor Therapeutics Trading Up 24.1%

CAPR stock traded up $2.14 during trading on Wednesday, hitting $11.01. The company had a trading volume of 8,156,062 shares, compared to its average volume of 3,184,348. The stock has a market cap of $640.23 million, a PE ratio of -4.44 and a beta of 0.80. The business has a 50-day moving average of $8.06 and a 200-day moving average of $20.05. Capricor Therapeutics has a one year low of $2.96 and a one year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.29). Research analysts forecast that Capricor Therapeutics will post -1.71 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Montanova Capital LLC boosted its holdings in Capricor Therapeutics by 7.2% in the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after acquiring an additional 274,184 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after acquiring an additional 361,664 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $5,397,000. Bank of New York Mellon Corp increased its holdings in shares of Capricor Therapeutics by 10.4% during the first quarter. Bank of New York Mellon Corp now owns 130,730 shares of the biotechnology company’s stock valued at $3,974,000 after acquiring an additional 12,366 shares in the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Capricor Therapeutics during the first quarter worth approximately $3,463,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Key Capricor Therapeutics News

Investors following CAPR have been watching these news items:

• Neutral Sentiment: Capricor outlined manufacturing validation work planned for 2027. This is relevant to potential commercialization, but also highlights that manufacturing readiness remains an execution consideration. Article: Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA
• Negative Sentiment: Third-quarter loss widened: Capricor reported a loss of $0.73 per share, missing the $0.44 loss analysts expected. The company also cut its workforce by 10%, underscoring pressure to manage costs. Article: Capricor Therapeutics Q3 Net Loss Widens; Cuts Workforce by 10%
• Negative Sentiment: A Seeking Alpha contributor argued that FDA objections have worsened the risk-reward outlook for Capricor, reflecting concerns about the regulatory path despite the approaching decision. Article: Capricor: The FDA’s Objections Change My June Buy To A Sell

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.